BR112018009645A2 - composições e métodos para a expressão de vários polipeptídeos biologicamente ativos a partir de um único vetor para tratamento de condições cardíacas e outras patologias - Google Patents
composições e métodos para a expressão de vários polipeptídeos biologicamente ativos a partir de um único vetor para tratamento de condições cardíacas e outras patologiasInfo
- Publication number
- BR112018009645A2 BR112018009645A2 BR112018009645A BR112018009645A BR112018009645A2 BR 112018009645 A2 BR112018009645 A2 BR 112018009645A2 BR 112018009645 A BR112018009645 A BR 112018009645A BR 112018009645 A BR112018009645 A BR 112018009645A BR 112018009645 A2 BR112018009645 A2 BR 112018009645A2
- Authority
- BR
- Brazil
- Prior art keywords
- conditions
- compositions
- treatment
- biologically active
- methods
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000013598 vector Substances 0.000 title abstract 2
- 230000000747 cardiac effect Effects 0.000 title 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 230000002491 angiogenic effect Effects 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013604 expression vector Substances 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 102000040430 polynucleotide Human genes 0.000 abstract 1
- 108091033319 polynucleotide Proteins 0.000 abstract 1
- 239000002157 polynucleotide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1738—Calcium binding proteins, e.g. calmodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/195—Chemokines, e.g. RANTES
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4728—Calcium binding proteins, e.g. calmodulin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/002—Vectors comprising a special translation-regulating system controllable or inducible
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/007—Vectors comprising a special translation-regulating system cell or tissue specific
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Marine Sciences & Fisheries (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
a presente invenção propõe composições e métodos úteis para tratar transtornos passíveis de terapia pela introdução de vetores de expressão multigênicos. mais especificamente, a invenção propõe vetores e polinucleotídeos que codificam polipeptídeos para o tratamento de transtornos cardíacos, em que os referidos polipeptídeos podem compreender uma citocina, uma quimiocina e/ou um polipeptídeo angiogênico, ou derivados funcionais desses. também são propostos, em composições da invenção, ligantes úteis para conectar e expressar polipeptídeos funcionais (biologicamente ativos) oriundos de estruturas de expressão multigênicas simples.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562254139P | 2015-11-11 | 2015-11-11 | |
PCT/US2016/061668 WO2017083750A1 (en) | 2015-11-11 | 2016-11-11 | Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018009645A2 true BR112018009645A2 (pt) | 2018-11-13 |
Family
ID=57543150
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018009645A BR112018009645A2 (pt) | 2015-11-11 | 2016-11-11 | composições e métodos para a expressão de vários polipeptídeos biologicamente ativos a partir de um único vetor para tratamento de condições cardíacas e outras patologias |
Country Status (14)
Country | Link |
---|---|
US (3) | US11154622B2 (pt) |
EP (1) | EP3387010A1 (pt) |
JP (1) | JP6976244B2 (pt) |
KR (1) | KR20180069081A (pt) |
CN (1) | CN108713025A (pt) |
AU (1) | AU2016353342B2 (pt) |
BR (1) | BR112018009645A2 (pt) |
CA (1) | CA3004742A1 (pt) |
HK (1) | HK1259137A1 (pt) |
MA (1) | MA43404A (pt) |
MX (1) | MX2018005886A (pt) |
RU (1) | RU2758489C2 (pt) |
SG (1) | SG11201803934YA (pt) |
WO (1) | WO2017083750A1 (pt) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL267865B2 (en) | 2017-01-10 | 2024-07-01 | Intrexon Corp | Modulation of expression of polypeptides through a new system for changing gene expression |
JP7240749B2 (ja) * | 2017-09-29 | 2023-03-16 | ベスファジェン・インコーポレイテッド | 心不全の予防または治療のための医薬組成物 |
EP3762010A4 (en) | 2018-03-06 | 2022-04-06 | Precigen, Inc. | HEPATITIS B VACCINES AND USES THEREOF |
US20210220463A1 (en) * | 2018-05-18 | 2021-07-22 | UNIVERSITé LAVAL | Vectors for dna vaccination |
KR20210018321A (ko) * | 2018-05-25 | 2021-02-17 | 더 위스타 인스티튜트 | 종양 특이적 신생항원 및 이를 사용하는 방법 |
SG11202103234RA (en) | 2018-10-01 | 2021-04-29 | Adicet Bio Inc | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON-ENGINEERED γδ -T CELLS FOR TREATMENT OF SOLID TUMORS |
WO2020072536A1 (en) | 2018-10-01 | 2020-04-09 | Adicet Bio, Inc. | COMPOSITIONS AND METHODS REGARDING ENGINEERED AND NON- ENGINEERED γδ-Τ CELLS FOR TREATMENT OF HEMATOLOGICAL TUMORS |
KR20220007043A (ko) * | 2019-03-29 | 2022-01-18 | 아비오메드, 인크. | 생물학 요법 또는 벡터 유전자 요법에서 좌심실 언로딩을 위한 시스템 및 방법 |
CA3106735A1 (en) * | 2019-05-21 | 2020-11-26 | Universite Laval | Crimean-congo hemorrhagic fever virus immunogenic compositions |
AU2020350140A1 (en) * | 2019-09-20 | 2022-03-31 | Ucl Business Ltd | Gene therapy composition and treatment of right ventricular arrythmogenic cardiomyopathy |
EP4192487A1 (en) * | 2020-08-07 | 2023-06-14 | Spacecraft Seven, LLC | Plakophilin-2 (pkp2) gene therapy using aav vector |
US11781156B2 (en) * | 2020-10-09 | 2023-10-10 | Tenaya Therapeutics, Inc. | Plakophillin-2 gene therapy methods and compositions |
AU2022325237A1 (en) * | 2021-08-12 | 2024-03-21 | Renovacor, Inc. | Retrograde coronary venous or sinus administration of therapeutics |
WO2023232984A1 (en) * | 2022-06-02 | 2023-12-07 | Patrick Most | S100a1 protein for use in treating and preventing infarct extension |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4985461A (en) | 1985-10-21 | 1991-01-15 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
US5117057A (en) | 1985-10-21 | 1992-05-26 | Rohm And Haas Company | Insecticidal N' substituted-N-N'-disubstituted-hydrazines |
US5225443A (en) | 1986-05-01 | 1993-07-06 | Rohm And Haas Company | Insecticidal N'-substituted-N'-substituted N,N'-diacylhydrazines |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
IL100643A (en) | 1991-01-25 | 1996-10-31 | Nippon Kayaku Kk | History of hydrazine and pesticides containing these histories as an active ingredient |
US5530028A (en) | 1992-11-23 | 1996-06-25 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-diacylhydrazines |
US6013836A (en) | 1992-02-28 | 2000-01-11 | Rohm And Haas Company | Insecticidal N'-substituted-N,N'-disubstitutedhydrazines |
MXPA02009157A (es) | 2000-03-22 | 2004-04-05 | Rohm & Haas | Nuevo sistema de expresion genetica inducible a base del receptor de ecdisona. |
US20040033600A1 (en) | 2001-03-21 | 2004-02-19 | Palli Subba Reddy | Ecdysone receptor-based inducible gene expression system |
US8105825B2 (en) | 2000-10-03 | 2012-01-31 | Intrexon Corporation | Multiple inducible gene regulation system |
AU2002247184B2 (en) | 2001-02-20 | 2008-06-19 | Intrexon Corporation | Novel ecdysone receptor/invertebrate retinoid X receptor-based inducible gene expression system |
ES2422303T3 (es) | 2001-02-20 | 2013-09-10 | Intrexon Corp | Receptores mutantes por sustitución novedosos y su uso en un sistema de expresión génica inducible basado en receptores nucleares |
JP4955905B2 (ja) | 2001-02-20 | 2012-06-20 | イントレキソン コーポレーション | キメラレチノイドx受容体および新規エクジソン受容体−ベースの誘導性遺伝子発現システムにおけるそれらの使用 |
EP1534738B1 (en) | 2001-02-20 | 2012-06-20 | Intrexon Corporation | Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
US20030027751A1 (en) * | 2001-04-10 | 2003-02-06 | Genvec, Inc. | VEGF fusion proteins |
CA2820144C (en) | 2001-09-26 | 2017-06-20 | Intrexon Corporation | Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof |
CA2459807C (en) | 2001-09-26 | 2013-09-03 | Jianzhong Zhang | Whitefly ecdysone receptor nucleic acids, polypeptides, and uses thereof |
US7375093B2 (en) | 2002-07-05 | 2008-05-20 | Intrexon Corporation | Ketone ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7304161B2 (en) | 2003-02-10 | 2007-12-04 | Intrexon Corporation | Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex |
US7304162B2 (en) | 2003-02-21 | 2007-12-04 | Intrexon Corporation | Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7456315B2 (en) | 2003-02-28 | 2008-11-25 | Intrexon Corporation | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex |
US7935510B2 (en) | 2004-04-30 | 2011-05-03 | Intrexon Corporation | Mutant receptors and their use in a nuclear receptor-based inducible gene expression system |
US9034650B2 (en) | 2005-02-02 | 2015-05-19 | Intrexon Corporation | Site-specific serine recombinases and methods of their use |
PT2043662E (pt) | 2006-07-26 | 2015-11-25 | Intrexon Corp | Métodos e composições para tratamento de doença |
WO2008088870A1 (en) | 2007-01-19 | 2008-07-24 | Progressive Gaming International Corporation | Table monitoring identification system, wager tagging and felt coordinate mapping |
RU2490253C2 (ru) | 2007-05-29 | 2013-08-20 | Интрексон Корпорейшн | Хиральные диацилгидразиновые лиганды для модуляции экспрессии экзогенных генов с помощью экдизон-рецепторного комплекса |
CN101868241A (zh) * | 2007-09-28 | 2010-10-20 | 英特瑞克斯顿股份有限公司 | 表达生物治疗分子的治疗基因开关构建物和生物反应器以及它们的应用 |
MX2010003720A (es) | 2007-10-08 | 2010-10-20 | Intrexon Corp | Celulas dendriticas creadas por ingenieria genetica y usos para el tratamiento de cancer. |
WO2009114702A2 (en) * | 2008-03-14 | 2009-09-17 | Humanzyme Limited | Recombinant production of authentic human proteins using human cell expression systems |
EP2356219A4 (en) | 2008-10-08 | 2017-07-05 | Intrexon Corporation | Engineered cells expressing multiple immunomodulators and uses thereof |
US20120283315A1 (en) | 2009-08-28 | 2012-11-08 | Penn Marc S | Sdf-1 delivery for treating ischemic tissue |
MX362513B (es) | 2010-03-23 | 2019-01-22 | Intrexon Corp | Vectores que expresan de manera condicional proteinas terapeuticas, celulas hospedadoras que comprenden vectores, y usos de los mismos. |
SG192856A1 (en) | 2011-03-04 | 2013-09-30 | Intrexon Corp | Vectors conditionally expressing protein |
US10420832B2 (en) * | 2012-11-16 | 2019-09-24 | United Biomedical, Inc. | Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD) |
WO2014089121A2 (en) * | 2012-12-03 | 2014-06-12 | Thomas Ichim | Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases |
AU2014233229A1 (en) | 2013-03-15 | 2015-09-17 | Juventas Therapeutics, Inc. | Retrograde delivery of SDF-1 for treatment of myocardial infarction |
WO2016187585A1 (en) | 2015-05-20 | 2016-11-24 | Viventia Bio Inc. | Deimmunized linker and methods of use |
CN105754990A (zh) * | 2016-01-29 | 2016-07-13 | 深圳精准医疗科技有限公司 | 一种pd-1/ctla-4双特异性抗体的制备方法及其应用 |
-
2016
- 2016-11-11 JP JP2018524443A patent/JP6976244B2/ja active Active
- 2016-11-11 BR BR112018009645A patent/BR112018009645A2/pt active Search and Examination
- 2016-11-11 SG SG11201803934YA patent/SG11201803934YA/en unknown
- 2016-11-11 RU RU2018117674A patent/RU2758489C2/ru active
- 2016-11-11 CA CA3004742A patent/CA3004742A1/en active Pending
- 2016-11-11 EP EP16810130.1A patent/EP3387010A1/en not_active Withdrawn
- 2016-11-11 KR KR1020187016185A patent/KR20180069081A/ko unknown
- 2016-11-11 CN CN201680078586.0A patent/CN108713025A/zh active Pending
- 2016-11-11 MA MA043404A patent/MA43404A/fr unknown
- 2016-11-11 AU AU2016353342A patent/AU2016353342B2/en not_active Ceased
- 2016-11-11 MX MX2018005886A patent/MX2018005886A/es unknown
- 2016-11-11 WO PCT/US2016/061668 patent/WO2017083750A1/en active Application Filing
-
2018
- 2018-05-11 US US15/978,036 patent/US11154622B2/en active Active
-
2019
- 2019-01-22 HK HK19101096.0A patent/HK1259137A1/zh unknown
-
2021
- 2021-09-22 US US17/481,938 patent/US20220072159A1/en not_active Abandoned
-
2023
- 2023-10-12 US US18/485,838 patent/US20240148908A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN108713025A (zh) | 2018-10-26 |
MA43404A (fr) | 2018-10-17 |
KR20180069081A (ko) | 2018-06-22 |
AU2016353342B2 (en) | 2021-04-01 |
JP6976244B2 (ja) | 2021-12-08 |
MX2018005886A (es) | 2018-08-15 |
WO2017083750A1 (en) | 2017-05-18 |
US20220072159A1 (en) | 2022-03-10 |
JP2018536405A (ja) | 2018-12-13 |
RU2758489C2 (ru) | 2021-10-28 |
HK1259137A1 (zh) | 2019-11-29 |
AU2016353342A1 (en) | 2018-05-24 |
RU2018117674A (ru) | 2019-12-13 |
CA3004742A1 (en) | 2017-05-18 |
US20240148908A1 (en) | 2024-05-09 |
EP3387010A1 (en) | 2018-10-17 |
US11154622B2 (en) | 2021-10-26 |
SG11201803934YA (en) | 2018-06-28 |
US20180360992A1 (en) | 2018-12-20 |
RU2018117674A3 (pt) | 2020-04-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018009645A2 (pt) | composições e métodos para a expressão de vários polipeptídeos biologicamente ativos a partir de um único vetor para tratamento de condições cardíacas e outras patologias | |
PH12019500637A1 (en) | Calpain modulators and therapeutic uses thereof | |
BR112019007369A2 (pt) | anticorpos anti-lag-3 e métodos de uso dos mesmos | |
BR112019010943A2 (pt) | métodos para o tratamento do câncer compreendendo agentes de ligação a tigit | |
EP3674314A3 (en) | Apelin polypeptides | |
EP3735976A3 (en) | Therapeutic use of mitochondria and combined mitochondrial agents | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
BR112016024850A2 (pt) | composições e métodos para modulação da expressão 3 semelhante a antiopoietina | |
BR112016023698A2 (pt) | cartucho de prendedores incluindo extensões que têm configurações diferentes | |
MX2018005829A (es) | Composiciones para tratar el cabello. | |
BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
BR112018072545A2 (pt) | inibidores da arginase e suas aplicações terapêuticas | |
MX2018016257A (es) | Polipéptidos del receptor 3 del factor de crecimiento de fibroblastos solubles (sfgfr3) y usos de los mismos. | |
BR112016026842A2 (pt) | preparação compreendendo fator viii e peptídeos de fator de von willebrand | |
MX2017010883A (es) | Composicion para el tratamiento de la infertilidad. | |
JO3565B1 (ar) | الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها | |
WO2016020882A3 (en) | Angiopoetin-like 4 (angptl4) antibodies and methods of use | |
CL2020001846A1 (es) | Anticuerpos pac1 y sus usos | |
BR112016021233A2 (pt) | Tratamento com óxido nítrico de complexo da doença respiratória bovina e outras condições respiratórias | |
BR112018074478A2 (pt) | peptídeo antimicrobiano modificado derivado de um domínio rico em arginina | |
EA202192380A1 (ru) | Система емкостей и способ приготовления смеси веществ | |
BR112019024796A2 (pt) | Peptídeos e usos dos mesmos como agentes antivirais | |
BR112019004203A2 (pt) | construto, composição farmacêutica, e, métodos para inibir angiogênese e para tratar uma doença ou enfermidade em um indivíduo distinguido por vascularização excessiva. | |
PH12020550024A1 (en) | Pharmaceutical combinations comprising an anti bst-1 antibody and a cytidine analogue | |
PH12020500404A1 (en) | Composition for controlled ovarian stimulation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] |